de Arpe Celia Fortea, Homen Reynaldo, Valls-Carbó Adrian, Barrado Julia, Olmos-Mata Carolina, Pérez-Somarriba Juncal, Muñoz-Gomez Ana, Núñez-Orantos Maria Jose, Cabello-Clotet Noemí, Estrada Vicente
Hospital Clinico San Carlos, Madrid, Spain.
Centro de investigación biomédica en red en enfermedades infecciosas (CIBERINFEC), Madrid, Spain.
Eur J Clin Microbiol Infect Dis. 2025 Jun 13. doi: 10.1007/s10096-025-05150-4.
Nirmatrelvir/ritonavir (NMV/r) might reduce the risk of hospitalization or death due to SARS-CoV2. Indirect data suggest that antiviral use among non-hospitalized patients is low. The aim of the study is to determine the number of patients admitted for COVID-19 who met the criteria to receive NMV/r prior to admission but did not receive it. We analyzed clinical data from electronic medical records of 132 patients who were hospitalized due to Covid-19 from August to November 2023. Among the 88 patients eligible for NMV/r before hospitalization, only 3.8% received it, even though 24.3% had previous contact with the healthcare system. Among those who were eligible for treatment, a potential drug interaction was identified in 80.6%; NMV/r was contraindicated in only ten cases (11.3%) due to a serious interaction, as it was deemed impossible to stop or alter it. Of the patients who did not receive treatment, three died from Covid-19, while there were no deaths in the treatment group. Our data confirm that many patients who could benefit from early treatment with NMV/r are not receiving it. This limited use may be linked to missed opportunities to prevent hospitalization and mortality from Covid-19.
奈玛特韦/利托那韦（NMV/r）可能会降低因严重急性呼吸综合征冠状病毒2（SARS-CoV2）导致的住院或死亡风险。间接数据表明，非住院患者中抗病毒药物的使用比例较低。本研究的目的是确定因新型冠状病毒肺炎（COVID-19）入院的患者中，那些在入院前符合接受NMV/r标准但未接受该治疗的患者数量。我们分析了2023年8月至11月因COVID-19住院的132例患者的电子病历临床数据。在88例住院前符合使用NMV/r条件的患者中，尽管有24.3%的患者此前曾与医疗系统接触，但只有3.8%的患者接受了该治疗。在符合治疗条件的患者中，80.6%的患者存在潜在药物相互作用；由于严重相互作用被认为无法停用或改变，仅10例（11.3%）患者禁忌使用NMV/r。在未接受治疗的患者中，有3例死于COVID-19，而治疗组无死亡病例。我们的数据证实，许多本可从NMV/r早期治疗中获益的患者并未接受该治疗。这种有限的使用可能与错过预防COVID-19住院和死亡的机会有关。
